Donor stem cell addback to speed immune recovery after transplant in leukemia patients
Tests returning donor stem cells after transplant to aid immune recovery in people with leukemia.
Key facts
- Who runs it
- Children's Hospital of Philadelphia
- Where
- Philadelphia, United StatesSee the site
- Trial code
- Registry title
- CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT
- Status
- Recruiting
- People taking part
- 50 people, planned
- Started
- 1 Mar 2019
- Expected to end
- Jul 2028
- Type of study
- Interventional, 2 groups
- Treatments tested
- CliniMACS Cell Processing System for TCRαβ + T Cell and CD45RA Depleted Peripheral Stem Cell Addback
- Record updated
- 8 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and young adults under 25 with high-risk blood cancers who are having a first stem cell transplant from a donor. It tests adding back a special group of donor cells.
- Age
- Under 25 years (the record gives a maximum age of 25 years).
- Sex
- All sexes can join.
- Disease stage
- Acute leukemia at high risk of coming back (for example leftover disease after treatment, high-risk gene findings, or relapse). Other blood cancers are also allowed: acute myeloid leukemia, myelodysplastic syndromes, acute lymphoblastic leukemia, mixed lineage leukemia, lymphoblastic lymphoma, Burkitt lymphoma, juvenile myelomonocytic leukemia.
- Earlier treatment
- This must be the first donor stem cell transplant. Organ and infection status must be checked as set by the transplant centre's procedure.
Main reasons for not taking part
- No suitable donor available for mobilized peripheral stem cells
- Genetic disorders such as Fanconi anemia, Kostmann syndrome, dyskeratosis congenita or other DNA repair defects
- Hodgkin lymphoma or lymphoma that is not Burkitt or lymphoblastic
- Pregnant participants
- Not meeting the centre's disease, organ or infection criteria
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Age: Patients <25 years
- First allogeneic HSCT only
- Disease eligibility: Acute leukemias at high risk for relapse including positive minimal residual disease at end consolidation, high risk cytogenetics, or relapse. Hematologic malignancies including: acute myeloid leukemia, myelodysplastic syndromes, acute lymphoblastic leukemia, mixed lineage or bi-phenotypic leukemia, lymphoblastic or Burkitts, juvenile myelomonocytic leukemia
- Evaluation of organ and infectious status as per our Bone Marrow Transplant standard operating procedure (BMT SOP)
- Signed consent by parent/guardian or able to give consent if >18 years
Who cannot take part
- Patients who do not meet institutional disease, organ or infectious criteria
- Patients with genetic disorders including Fanconi anemia, Kostmann syndrome, dyskeratosis congenital or other DNA repair defects
- No suitable donor available for mobilized peripheral stem cells
- Patients with Hodgkin lymphoma or non-Burkitts, non-lymphoblastic lymphoma
- Pregnant Participants; Donor selection and eligibility
- Unrelated donor meets National Marrow Donor Program criteria for donation
- HLA testing/matching
- Donor must be willing to undergo granulocyte colony stimulating factor (GCSF) mobilization and peripheral blood stem cell collection
Where in United States
- Children's Hospital of PhiladelphiaPhiladelphia, United StatesContact: Megan AtkinsonTaking people
About the trial
What the trial wants to find out
The major morbidities of allogeneic hematopoietic stem cell transplant with non-human leukocyte antigen (HLA) matched siblings are graft vs host disease (GVHD) and life threatening infections. T depletion of the donor hematopoietic stem cell graft is effective in preventing GVHD, but immune reconstitution is slow, increasing the risk of infections. An addback of donor CD45RA (naive T cells) depleted cells may improve immune reconstitution and help decrease the risk of infections.
The 2 groups in the trial
- TBI regimenOther group
Standard of care myeloablative regimens will be used based on disease type and clinical status at time of transplant. Patients with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma will receive total body irradiation (TBI) regimen (thiotepa, cyclophosphamide, TBI).
Treatment: CliniMACS Cell Processing System for TCRαβ + T Cell and CD45RA Depleted Peripheral Stem Cell Addback
- TBI or busulfan regimenOther group
Standard of care myeloablative regimens will be used based on disease type and clinical status at time of transplant. Patients not diagnosed with ALL or lymphoblastic lymphoma may receive either total body irradiation (TBI) regimen (thiotepa, cyclophosphamide, TBI) or busulfan containing regimen (thiotepa, cyclophosphamide, busulfan).
Treatment: CliniMACS Cell Processing System for TCRαβ + T Cell and CD45RA Depleted Peripheral Stem Cell Addback
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- CD45RA Depleted Peripheral Stem Cell Addback for Patients at Risk for Viral or Fungal Infections Post TCRαβ/CD19 Depleted Hematopoietic Stem Cell Transplant
- Plain-language title
- Donor stem cell addback to speed immune recovery after transplant in leukemia patientsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 8 July 2026